SynthesisThe international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease2016
Rifampicin resistance after treatment for latent tuberculous infection: a systematic review and meta-analysis.
Synthesis in The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 50 citations in OpenAlex.
- Cost-effectiveness of 3-months isoniazid and rifapentine compared to 9-months isoniazid for latent tuberculosis infection: a systematic review.BMC public health · 2022Pooled it
- 3-month daily rifampicin and isoniazid compared to 6- or 9-month isoniazid for treating latent tuberculosis infection in children and adolescents less than 15 years of age: an updated systematic review.The European respiratory journal · 2018Pooled it
- Rapid molecular testing or chest X-ray or tuberculin skin testing for household contact assessment of tuberculosis infection: A cluster-randomized trial.PLoS medicine · 2025Trial
- Embracing Tuberculosis Preventive Treatment: A Crucial Step towards TB Control in Pakistan.Pakistan journal of medical sciences · 2026Article
- Reappraising TB preventive treatment in India: programmatic and ethical implications of subclinical tuberculosis in household contacts.The Lancet regional health. Southeast Asia · 2026Review
- Reply to the letter on "Brazilian guidelines for the management of tuberculosis infection in immune-mediated inflammatory diseases: is retesting in latent tuberculosis screening appropriate and safe?"Advances in rheumatology (London, England) · 2025Article
- Latent Tuberculosis Treatment among Hard-to-Reach Ethiopian Immigrants: Nurse-Managed Directly Observed versus Self-Administered Isoniazid Therapy.Tropical medicine and infectious disease · 2023Article
- Latent tuberculosis infection treatment completion in Biscay: differences between regimens and monitoring approaches.Frontiers in medicine · 2023Article
- Potential Impact of Long-Acting Products on the Control of Tuberculosis: Preclinical Advancements and Translational Tools in Preventive Treatment.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Article
- Testing and Scaling Interventions to Improve the Tuberculosis Infection Care Cascade.Journal of the Pediatric Infectious Diseases Society · 2022Review
- Article
- Four months of rifampicin monotherapy for latent tuberculosis infection in children.Clinical and experimental pediatrics · 2022Article
- WHO target product profiles for TB preventive treatment.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2022Article
- Clinical standards for the diagnosis, treatment and prevention of TB infection.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2022Article
- Subclinical Tuberculosis: Some Flies in the Ointment.American journal of respiratory and critical care medicine · 2021Article
- Treatment of Latent Tuberculosis Infection-An Update.Clinics in chest medicine · 2019Review
- No evidence of increased risk of acquired rifampin resistance.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2019Article
- Management of Latent Tuberculosis Infection in Children from Developing Countries.Indian journal of pediatrics · 2019Review
- Responsible use of rifampin for the treatment of latent tuberculosis infection.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2019Article
- Treatment of Latent Tuberculosis Infection.Microbiology spectrum · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
settingTreatment for latent tuberculous infection (LTBI) reduces the risk of tuberculosis (TB) disease. Shorter, rifamycin-containing regimens have been shown to be as effective as 6 months of isoniazid and superior with regard to safety and completion rate. It is unknown whether preventive therapy with rifamycins increases resistance to the drugs used.
objectiveTo determine whether treatment for LTBI with rifamycin-containing regimens leads to significant development of resistance against rifamycins.
designSystematic review and meta-analysis.
resultsWe included six randomised-controlled trials of rifamycin-containing regimens for LTBI treatment that reported drug resistance. There was no statistically significant increased risk of rifamycin resistance after LTBI treatment with rifamycin-containing regimens compared to non-rifamycin-containing regimens (RR 3.45, 95%CI 0.72-16.56; P = 0.12) or placebo (RR 0.20, 95%CI 0.02-1.66; P = 0.13).
conclusionPreventive treatment with rifamycin-containing regimens does not significantly increase rifamycin resistance. Programmatic management of LTBI requires the creation of sound surveillance systems to monitor drug resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.